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The CCAAT/enhancer binding protein (C/EBP) family of tran-
scription factors is a group of six known proteins: C/EBPa
(C/EBP), C/EBPb (NF-IL6, LAP), C/EBPg (Ig-EBP), C/EBPd
(NF-IL6b), C/EBPe (CRP-1) and C/EBPz (CHOP, GADD153)
(Vinson et al, 1993). These proteins consist of three domains: a
DNA-binding domain, a regulatory domain and a dimerization
domain. The dimerization domains of the different family
members have a high degree of homology. This domain is a
leucine-zipper motif that allows the C/EBP to dimerize as both
homo- and heterodimers. They can also form heterodimers with
other leucine-zipper proteins in the Fos/Jun family and the
ATF/CREB family (Vinson et al, 1993). The DNA-binding regions
of the dimerized proteins recognize a palindromic CCAAT motif
in the promoter of target genes. However, heterodimerization of
any of the family members with C/EBPz directs the complex away
from this binding site because C/EBPz has a different DNA-
binding domain (Ron and Habener, 1992). There are also shorter
forms of C/EBPa and -b, which lack this DNA-binding domain.
These truncated forms may also act as inhibitors of transcriptional
activation (Descombes and Schibler, 1991; Lin et al, 1993).
The roles of the C/EBP family in the control of proliferation and
differentiation have mostly been studied in vitro in adipocytes
(Cao et al, 1991; Umek et al, 1991). These in vitro studies demon-
strated that the b- and d-forms were active during the proliferative
stages in the transition of preadipocytes into adipocytes prior to
the activation of C/EBPa, which was expressed exclusively in
the terminally differentiated cells. A constitutive expression of
C/EBPa was also necessary to maintain adipocytes in their differ-
entiated stage, when C/EBPa also acted as an antimitotic factor
(McKnight, 1991; Samuelsson et al, 1991). C/EBPz has also the
potential to act as an inhibitor of the transcription by blocking
DNA binding of other C/EBPs through dimerization (Ron and
Habener, 1992). This dimerization results in a reduction of the
differentiation process in vitro (Batchvarova et al, 1995).
The C/EBP family is also involved in the differentiation process
of other cell types, e.g. intestinal epithelium (Chandrasekaran and
Gordon, 1993), ovarian follicles (Piontkewitz et al, 1993), type II
alveolar cells of the lung (Li et al, 1995) and myeloid cells (Scott
et al, 1992). The involvement of these transcription factors in
human diseases is largely unknown, although a fusion protein
containing C/EBPz has been reported in myxoid liposarcoma
(￿man et al, 1992).
Ovarian tumours are the cause of 6% of deaths from malignan-
cies in women in the Western hemisphere (Silverberg, 1984). Over
80% of these cancers originate from the surface (germinal) epithe-
lium of the ovary (OSE cells). These carcinomas are suggested to
originate from transformed OSE cells, either as a consequence of
the repeated degradation and reconstitution of the ovarian surface
after each ovulation or as the result of the formation of inclusion
cysts with entrapped OSE cells (Hamilton, 1992).
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Summary The CCAAT/enhancer binding protein (C/EBP) family of transcription factors is involved in metabolism and differentiation of cells,
especially in rodent liver cells and adipocytes. Their roles in vivo and in particular during pathophysiological conditions in humans are largely
unknown. We have investigated the presence of C/EBPa, -b, -d and -z in normal ovaries and in epithelial ovarian tumours of different stages.
Immunohistochemical experiments demonstrated that C/EBPa and C/EBPb were preferentially expressed in epithelial/tumour cells
irrespective of stage or grade of the tumour. C/EBPb was located in the nuclei of the cells, in contrast to C/EBPa, which was present only in
the cytoplasm of these cells. The nuclear localization of C/EBPb indicates an active role of this transcription factor in tumour cells, whereas
the cytoplasmic distribution suggests a more passive function of C/EBPa. C/EBPd and -z demonstrated a more diverse distribution with
predominant localization to epithelial cells, but stromal distribution was also noted. The intracellular distribution was confined to both the
nucleus and the cytoplasm for C/EBPd and -z. Western blotting demonstrated that C/EBPa, -b, -d and -z were present in a majority of the
samples. The amount of C/EBPb increased markedly with malignancy, i.e. with degree of dedifferentiation, while the other members of the
C/EBP family displayed a more constant expression level. These results demonstrate an association between the expression of members of
the C/EBP family and the formation of epithelial ovarian tumours, with C/EBPb as a potential marker for these tumours. As C/EBPb is known
to be expressed during proliferation of cells in vitro, it may participate in the proliferative process of ovarian epithelial tumour cells in vivo and
play a central role in tumour progression.
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We have studied the expression of four of the members of the
C/EBP family members (C/EBPa, -b, -d, -z) in tissue specimens of
ovarian epithelial tumours of different grades and stages in order to
elucidate possible roles of these transcription factors in tumour
formation in vivo. The specimens were analysed for cell-specific
localization by immunohistochemistry and further quantified by
Western blotting.
MATERIALS AND METHODS
Human tissues
Biopsies from normal ovaries and tumour tissues of ovarian origin
were obtained from 35 patients undergoing laparotomy (approved
by the Ethics Committee of the Medical Faculty, G￿teborg
University). The material is described in Table 1. Tissues were
immediately washed in ice-cold 0.9% sodium chloride, snap-
frozen in liquid nitrogen and stored at —70° C until analysis. All
samples were examined by two independent and experienced
pathologists for diagnosis.
Primary antibodies
The following antibodies/antiserum were used: C/EBPa (rabbit
polyclonal, cat. no. sc-61 and a rabbit antiserum provided by SL
McKnight, Dallas, TX, USA), C/EBPb (rabbit polyclonal, cat. no.
sc-150), C/EBPd (rabbit polyclonal, cat. no. sc-151), C/EBPz
(GADD153) (rabbit polyclonal, cat. no. sc-793) and proliferating
cell nuclear antigen (PCNA, mouse monoclonal, cat. no. sc-56).
All antibodies were from Santa Cruz Biotechnology (San Diego,
CA, USA). The antiserum against C/EBPa was used for immuno-
histochemistry (Piontkewitz et al, 1993). All C/EBP antibodies
were diluted 1:500 for Western blotting and 1:100 for immuno-
histochemistry. The dilution of the PCNA antibody was 1:500.
Cytokeratin AE1/AE3 monoclonal antibody was used at a dilution
of 1:40 (Cat. no. 1124161, Boehringer Mannheim, Germany).
Immunohistochemistry
Fresh-frozen tissues were cryosectioned and fixed in cold acetone
at —20°C for 10 min, then dried at room temperature. The slides
were then hydrated with cold phosphate-buffered saline (PBS) and
blocked with 5% non-fat milk (NFM) for 30 min, before the addi-
tion of the primary antibodies diluted in buffer solution [PBS with
1% bovine serum albumin (BSA), 0.2% Triton X-100, 0.1%
sodium azide], and left overnight at room temperature. Bound
antibodies were visualized by biotinylated secondary horse anti-
rabbit (C/EBP) or anti-mouse (cytokeratin) antibodies (Vector,
Burlingham, CA, USA) and streptavidin—fluorescein isothio-
cyanate (FITC, Amersham, Buckinghamshire, UK). Sections were
mounted with Moviol/Dabco mounting medium (0.4% Moviol,
Hoechst, Frankfurt am Main, Germany) in 30% glycerol with the
addition of 2.5% Dabco (4-diazabicyclo (2.2.2) octane; Fluka,
Buchs, Switzerland) (Piontkewitz et al, 1993). In the control
sections, which showed only negligible signals, the first antibody
was replaced by 5% NFM (data not shown). The sections were
viewed and photographed with a Nikon microphot FX fluores-
cence microscope. All sections were stained with an antibody
against cytokeratin to verify the epithelial origin of cells.
Western blotting
Soluble tissues were prepared by homogenization in a PE buffer
(10 mM potassium phosphate buffer, pH 6.8, and 1 mM EDTA)
containing 10 mM 3-(3-cholamidopropyl)dimethyl-ammonio 
1-propane sulphate (CHAPS), aprotinin (200 kallikrein inhibitory
units per ml), leupeptin (1 mg ml—1), pepstatin (1 mg ml—1) and
Pefablock¤ (1 mg ml—1) (Boehringer Mannheim, Germany). The
homogenate was then sonicated (twice, for 15 s each time) and
centrifuged (10 000 g, 10 min, 4°C). Supernatants were stored at
—70°C until analysis. The protein concentrations were measured
according to Lowry. The samples were diluted in sodium dodecyl
sulphate (SDS) sample buffer and heated at 95°C for 5 min before
loading on a SDS-polyacrylamide gel (12% Tris-glycine)
(NOVEX, San Diego, CA, USA). Fifty micrograms of total
protein was loaded into each lane. The proteins were transferred to
a polyvinyldifluoride membrane (Amersham, Buckinghamshire,
UK) using a blotting system (NOVEX). The membrane was then
incubated with specific antibodies. Prestained standards (SeeBlue,
NOVEX) were used as weight markers. Immunoreactive protein
was visualized by chemiluminescence using alkaline phosphatase-
conjugated secondary goat anti-rabbit antibodies (dilution:
1:20 000) or goat anti-mouse antibodies (dilution 1:10 000) (Santa
Cruz Biotechnology), and CSPD or CDP Star (Tropix, Bedford,
MA, USA) as substrate. The membrane was exposed to ECL film
Table 1 List of tissues analysed for C/EBPa, -b, -d and -z
Sample no. Type Stage abdz
N1 N Normal, fertile W W W W
N2 N Normal, fertile W W W W
N3 N Normal, fertile W W W
N4 N Normal, post-menopausal W W W W
N5 N Normal, post-menopausal I I I I
N6 N Normal, post-menopausal I I I I
N7 N Normal, post-menopausal I I I I
Tb1 B Adenoma I I I I
T8 B Adenofibroma W W W W
T12 B Adenofibroma W,I W,I W,I W,I
T17 B Adenoma W W W
T36 B Adenofibroma I I I I
T5 BL Borderline adenofibroma IA W W W W
T16 BL Borderline adenoma IA W,I W,I W,I W,I
T20 BL Borderline adenoma IA I I I I
T32 BL Borderline muc. adenoma IA I I I I
T22 M h diff. ser. adenocarcinoma III I I I I
T25 M h diff. ser. adenocarcinoma III I I I I
T34 M h diff. muc. adenocarcinoma IA I I I I
T9 M m/p diff. ser. adenocarcinoma III W,I W W,I W,I
T15a M m/p diff. ser. adenocarcinoma III W,I I I W
T15b M Metastasis t. 15a III W W W
T29 M m diff. ser. adenocarcinoma III I I I I
T30 M m diff. ser. adenocarcinoma III I I I I
T31 M m diff. ser. adenocarcinoma III I I I I
T11 M m/p diff. ser. adenocarcinoma II W W W W
T10a M m/p diff. ser. adenocarcinoma III W W W
T10b M Metastasis t. 10a III W W W
T14 M p diff. ser. adenocarcinoma III W W W W
T26 M p diff. ser. adenocarcinoma II I I I I
T27 M p diff. ser. adenocarcinoma IC I I I I
T33 M p diff. ser. adenocarcinoma III I I I I
T35 M p diff. ser. adenocarcinoma III I I I I
T18 M Undiff. adenocarcinoma III W,I W,I W,I W,I
T28 M undiff. adenocarcinoma I I I I I
Abbreviations: W, Western blotting performed; I, immunohistochemistry
performed; N, normal; B, benign; BL, borderline; M, malignant; h, highly; m,
moderately; p, poorly; diff, differentiated; ser, serous; muc, mucinous.(Amersham, Buckinghamshire, UK) at room temperature. For
semiquantitative measurement of proteins on these Western blots,
a software package (Quantity One, PDI, NY, USA) in The
Discovery Series Densitometric Systems (Pharmacia Biotech,
Lund, Sweden) with Desk Top Plus Scanner, were used. The
optical density (OD) ´ mm from each band was measured.
Statistical difference was evaluated by t-test (two sample) and a
value of P < 0.05 was considered to be significant (Altman, 1991).
RESULTS
C/EBPa
The immunohistochemical analyses included 23 samples (Table
1). C/EBPa was detected mainly as a cytoplasmic staining in all of
the tumours and also in the normal ovaries. Nuclear staining was
only apparent in adipose cells adjacent to the tumour tissue (Figure
1C). The expression was restricted to epithelial cells in most of the
samples (Figure 2A, D), and staining of the stroma cells was
demonstrated in only two of the samples (T31 and T52). CEBPa
was also expressed in the epithelial cell layers of inclusion cysts
(N5 and T12). The intensity of the staining was rather constant in
the different tumour samples and did not appear to be related to
stage or grade of the tumour.
The Western blotting analyses of C/EBPa included 17 samples
(Table 1). The expression of C/EBPa was constant in all samples,
with a slightly lower content in the undifferentiated tumour
(Figure 5B). In addition to the expected band with a molecular
weight of 42 kDa, a band of 30 kDa was detected in all samples,
except in the undifferentiated tumour. This band represents a
shorter form of the protein, lacking a part of its activating region
(Lin et al, 1993). A constant band of approximately 50 kDa was
also noted in all samples. This signal [C/EBP reactive material
(CRM, Cao et al, 1991)] was unrelated to normal or tumour
tissues. This band was also present in other cell types and species
(data not shown).
C/EBPb
In the normal ovary, the OSE cells at the ovarian surface expressed
minute amounts of C/EBPb, whereas epithelial cells of cleft
formations and inclusion cysts were positively stained (Figure 3).
An intense staining was demonstrated in all tumours and the
expression of C/EBPb was restricted to the epithelial cells, regard-
less of the tumour type. Stromal staining was demonstrated in only
four samples (T29, T31, T32 and T52), and this signal was less
intense than in the epithelial cells. C/EBPb expression was more
pronounced in the malignant samples, although it was detected at
all stages of dedifferentiation and in all grades (Figure 4).
Furthermore, the immunohistochemical analyses of 22 samples
(Table 1) revealed a different intracellular distribution of C/EBPb
compared with that of C/EBPa. C/EBPb was localized to the
nucleus in the majority of tumour cells in the malignant samples
(Figures 1D, 4), in contrast to C/EBPa, which demonstrated
mainly a cytoplasmic staining. In the inclusion cysts (N5 and
T12), both cytoplasmic and nuclear staining was observed for
C/EBPb (Figure 3B).
The presence of C/EBPb was investigated by Western blotting
in 14 samples (Table 1). The intact, full-length protein was
detected as two bands, at 34 kDa and 38 kDa. The two normal
ovaries expressed C/EBPb, while the benign and borderline
samples contained minute amounts of the protein. All the malig-
nant samples contained large amounts of C/EBPb (Figure 5A). In
fact, the expression in the malignant samples was significantly
higher (P < 0.01) than in normal ovaries and benign/borderline
tumours. In addition, the malignant tumours contained a band at
18 kDa, representing the shorter form of the protein, LIP
(Descombes and Scibler, 1991). The pattern of expression of
C/EBPb with an increased content in the malignant tumours corre-
lated with that of PCNA (Figure 6).
C/EBPd
Immunohistochemical analyses of 23 tissue sections (Table 1) for
C/EBPd revealed staining of epithelial cells, while stromal
staining was detected in 13 of these tumours (56%). In some of the
sections, the stromal signals appeared as dots (Figure 2B, E).
C/EBPd was detected in the nucleus in all samples (Figures 1E and
2B, E). The intensity of the staining was constant, although some
malignant tumours exhibited a stronger signal.
The contents of C/EBPd were analysed in 13 samples with
Western blotting (Table 1). The band of 30 kDa representing this
protein was present in all samples. The levels were variable and no
pattern related to degree of differentiation or grade could be
detected. The malignant tumours expressed an additional band of
36 kDa (Figure 5B).
C/EBPz
Immunohistochemical analyses included 22 samples (Table 1).
The staining was predominantly localized to the epithelial areas of
the tumours, although seven of the samples (32%) also demon-
strated C/EBPz signals in the stromal tissue (Figures 1F and 2C,
F). A faint staining was also demonstrated in the epithelial cells
of inclusion cysts. The intracellular localization of C/EBPz was
predominantly perinuclear in both epithelial and stromal cells.
These signals sometimes appeared as rings or dashes (data not
shown).
Western blotting of 17 samples (Table 1) demonstrated C/EBPz
as a 29-kDa band. The expression was slightly higher in the malig-
nant tumours than in normal ovaries and benign tumours, although
the difference was not as pronounced as for C/EBPb. In addition,
a band of approximately 20 kDa was visible in the malignant
tumours (Figure 5B).
DISCUSSION
We have investigated the presence of four members of the C/EBP
family in epithelial ovarian tumours and normal ovaries. In this
study, we found that the expression of C/EBPb was more
pronounced in malignant tumours than in benign and borderline
tumours. These differences in the contents were correlated with
the expression of PCNA, a marker for cell proliferation (Takasaki
et al, 1981), in the same samples. As C/EBPb is known to be
expressed in cells in vitro at proliferative and not fully
differentiated stages, this finding also suggests a role for C/EBPb
during increased proliferation of tumour cells, similar to the
proposed function of classical oncogenes and transcription factors
in tumorigenesis.
The C/EBPb protein was detected as two bands of the full-
length protein (LAP) at 34 kDa and 38 kDa. Multiple forms of
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LAP (30—40 kDa) were demonstrated in mouse mammary epithe-
lial cells (Raught et al, 1995). The appearance of such forms might
be attributed to post-translational modifications, e.g. phosphoryla-
tions. In fact, C/EBPb was demonstrated to be phosphorylated by
cyclic AMP-dependent protein kinase in vitro (Park et al, 1993)
and Ca2+ calmodulin-dependent protein kinases in vitro (Wegner et
al, 1992). The shorter form of C/EBPb (LIP, 18 kDa) was detected
only in the malignant samples, although this does not exclude the
presence of small amounts of the proteins in the normal ovary and
in the benign tumours. The two isoforms, LAP and LIP, are
explained by differential use of two AUGs within the same tran-
script (Descombes and Schibler, 1991). LIP is probably not func-
tional as an activator of transcription, because the activational
domain in the N-terminal part of the protein is missing. More
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Figure 1 Detection of four members of the C/EBP family with immunohistochemistry in a moderately differentiated serous adenocarcinoma (T31)
(bar = 50 mm). (A) Negative control, (B) cytokeratin as a marker of epithelial cells, (C) C/EBPa, (D) C/EBPb, (E) C/EBPd and (F) C/EBPz1244 K Sundfeldt
British Journal of Cancer (1999) 79(7/8), 1240–1248 © Cancer Research Campaign 1999
AB C
DE F
Figure 2 Detection with immunohistochemistry (bar = 50 mm) of C/EBPa (A and D), C/EBPd (B and E) and C/EBPz (C and F), in a post-menopausal normal
ovary (N5); surface epithelium (A–C), epithelial cells lining a cleft formation (D–F)
AB C
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Figure 3 Detection of C/EBPb in a post-menopausal normal ovary (N5) with immunohistochemistry (bar = 50 mm) (A) surface epithelial cells, (B) inclusion
cyst, (C) cleft formation and (D–F) corresponding tissue sections incubated with antibodies against cytokeratin, a marker of epithelial cellsC/EBP in ovarian tumours 1245
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likely, the shorter form represses the functions of C/EBPb by the
formation of inactive dimers with the full-length protein. The ratio
between the two different forms of the C/EBPb was suggested
to be of importance for the transcriptional activity in mouse
mammary epithelial cells (Raught et al, 1995).
The immunohistochemical analyses revealed that the increased
expression of C/EBPb was preferentially localized to epithelial
cells within the tumours. However, invaginated OSE cells in cleft
formations and epithelial cells lining cysts also stained positive for
C/EBPb. The stromal compartments of normal ovaries and of
tumours stained negative almost without exception. The specific
appearance of C/EBPb in inclusion cyst is of interest for the patho-
genesis of epithelial ovarian tumours since such cysts have been
suggested to constitute the initial steps in tumour development
(Hamilton, 1992). The present results suggest a putative role for
C/EBPb in the initial, proliferative process but also later in tumori-
genesis of these cells in vivo. The low contents of C/EBPb in
benign tumours may indicate that these tumours represent a
different trait in tumour formation without the potential of malig-
nant transformation, or that their growth capacity is very low.
C/EBPb was present in the nucleus of the epithelial cells in all
samples. This was in contrast to C/EBPa which was mainly local-
ized to the cytoplasm. The localization of C/EBPb to the nucleus,
together with the increased levels of this protein, proposes an active
involvement in the transcriptional machinery of these cells.
However, cytoplasmic localization of transcription factors, as noted
for C/EBPa, may also reflect a regulatory pathway to inhibit tran-
scriptional activity. For example, the activity of the transcription
factor NFkB, is mainly regulated by shuttling of the protein
between cytoplasm and nucleus (Ghosh and Baltimore, 1990).
Such extranuclear localization of C/EBPa in malignant cells
suggests an ￿inactive￿ state of this transcription factor. In fact,
translocation of C/EBPa, C/EBPb and C/EBPd between the cyto-
plasm and nucleus was regulated by tumour necrosis factor a
(TNF-a) in hepatocytes in vitro (Yin et al, 1996). Interestingly, the
expression of TNF-a in ovarian tumours was demonstrated to be
positively correlated with tumour grade (Naylor et al, 1993). TNF-
a has also been described as a growth factor for the ovarian tumour
cells (Wu et al, 1993). These observations indicate that TNF-a
could be involved in the post-translational regulation of C/EBP
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Figure 4 Detection of C/EBPb in (A) epithelial cells of a borderline tumour (T16), (B) moderately differentiated adenocarcinoma (T30), (C) poorly differentiated
adenocarcinoma (T33) and (D) undifferentiated adenocarcinoma (T18) (bar = 50 mm)1246 K Sundfeldt
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proteins in ovarian tumour cells. Studies have also revealed that the
relocalization and transition of C/EBP into a nuclear, activated state
was dependent on phosphorylation, mediated by cyclic AMP-
dependent or Ca2+-dependent protein kinases (Metz and Ziff, 1991).
C/EBPb has mainly been found to induce expression of genes in
acute-phase responses (Akira et al, 1990; Poli et al, 1990), such as
granulocyte colony-stimulating factor (G-CSF) (Tanaka et al,
1995), interleukin (IL)-6 (Poli et al, 1990), and IL-8 (Matsusaka et
al, 1993). Interestingly, IL-6 was expressed at high levels in ovarian
tumours and stimulated proliferation of these cells (Watson et al,
1993). IL-8 was also measured in ovarian tumours, and the concen-
tration of the protein was markedly higher in cyst fluid from malig-
nant compared to benign tumours (Ivarsson et al, 1997). Both these
cytokines, IL-6 and IL-8, were regulated by C/EBPb in synergy
with NFkB (Matsusaka et al, 1993). Furthermore, the expression of
C/EBPb could be stimulated by inflammatory substances, e.g.
lipopolysacharides (LPS), IL-1 and IL-6 (Akira and Kishimoto,
1992). Recently, C/EBPb was connected with proteins involved in
the cell cycle, e.g. the tumour-suppressor retinoblastoma protein,
Rb. Rb was demonstrated to directly interact and activate C/EBPb
(Chen et al, 1996). Loss or altered expression of Rb was suggested
to be a primary event in many malignancies and this might also
influence the activity of C/EBPb. Studies in primary ovarian carci-
nomas demonstrated that Rb was normally expressed in a majority
of these tumours (Dodson et al, 1994). Therefore, a direct interac-
tion between Rb and C/EBPb is plausible in epithelial ovarian
tumour cells and suggests a role for C/EBPb in the control of the
cell cycle. In fact, a direct, cell cycle-regulated DNA-binding
activity of C/EBPb was demonstrated in regenerating rat hepato-
cytes in vivo (Rana et al, 1995).
Recently, the expression of the C/EBPb isoforms (LAP and LIP)
was examined in human breast tumours (Zahnow et al, 1997). It
was found that LIP was present in malignant tumours, which
stained negative for steroid receptors, suggesting that LIP might be
useful as a prognostic marker for the identification of patients with
a poor prognosis. C/EBPa was examined in liver carcinomas (Xu
et al, 1994), where it was localized to both the nucleus and cyto-
plasm of the tumour cells. The expression of the protein was
decreased when these tumours dedifferentiated. The anti-prolifer-
ating and anti-tumour properties of C/EBPa were demonstrated by
induction of C/EBPa in human tumour cell lines (Timchenko et al,
1996; Watkins et al, 1996). This induction was mediated by
increased levels of the cell cycle protein p21 (WAF-1), which is
also regulated by the tumour suppressor p53.
In addition to the interaction with other factors for the transcrip-
tional regulation of genes, the C/EBP proteins themselves affect
the function of each other in a complex manner. The different
members form both homo- and heterodimers, thereby extending
and altering their regulatory potential. One of the proteins,
C/EBPz, has a different DNA-binding domain from the other
members. Two amino acids in the basic region are replaced by
prolines, which makes them unable to recognize the classic
CCAAT sites. C/EBPz can therefore act as a potent inhibitor of the
other factors, directing them away from their target DNA (Ron and
Habener, 1992). C/EBPz was induced by cellular stress and inhib-
ited proliferation with a subsequent arrest of growth in the G1/S
checkpoint. A fusion protein, TLS-CHOP, which inhibited the
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Figure 5 Western blotting analysis of four members of the C/EBP family.
(A) C/EBPb (LAP 34 and 38 kDa, LIP 18 kDa) and the quantification by
densitometry (OD ´ mm, the result of sample 8 refers to lower blot). (B)
C/EBPa (42 kDa), C/EBPd (30 kDa) and C/EBPz (29 kDa). The samples: 1
and 2, normal post menopausal ovaries (N1, N4); 3 and 4, benign tumours
(T12, T8); 5, a borderline tumour (T5); 6–9, medium to poorly differentiated
malignant tumours (T11, T9, T10a, T14); and 10, undifferentiated malignant
tumour (T18)
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Figure 6 Comparison of Western blots for C/EBPb (LAP, 34/38 kDa and
LIP, 18 kDa) (top) and PCNA (36 kDa) (bottom). The samples: 1, T5; 2,
T10a; 3, T10b; 4, N1; 5, N2; 6, T14; 7, T16; 8, T17; 9, T18. Abbreviations:
N, normal ovary; B, benign tumour; BL, borderline tumour; M, malignant
tumournormal function of C/EBPz (CHOP) was demonstrated in myxoid
liposarcoma (￿man et al, 1992). The effect of C/EBPz in differen-
tiation was further investigated in 3T3-L1 cells that failed to
convert into adipocytes. This effect was mediated by a reduction in
C/EBPa gene expression (Batchvarova et al, 1995). In the present
study, there was a minor increase in the concentration of C/EBPz
in the more malignant samples. As the immunohistochemical
experiments revealed that most of the protein was localized
outside the nucleus, this factor may exert some of its inhibitory
potential in the cytoplasm, e.g. by binding to other leucine-zipper
proteins and thereby blocking their entrance into the nucleus. An
additional band of approximately 35 kDa was observed for
C/EBPd in the malignant tumours. Such a band might be attribut-
able to extensive phosphorylation resulting in an altered function
of the transcription factor (Park et al, 1993; Wegner et al, 1992).
However, further studies are needed to reveal the pattern of
phosphorylation of the different C/EBP proteins in tumour cells
and to examine the effect of such modifications on their transcrip-
tional activities.
In conclusion, the cell- and stage-specific pattern of expression
of C/EBPs in epithelial ovarian tumours suggests an involvement of
these transcription factors in tumour progression. Further studies
are needed to determine their specific actions in the transcriptional
machinery during dedifferentiation and proliferation of tumour
cells. Thus, this family of transcription factors has the potential to
be the target for both diagnostic and therapeutic development.
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